Colon Cancer PatientsNCT07620444
Spectral Precise Image-Colon Cancer
An observational study of Colon Cancer Patients, run by Philips Clinical & Medical Affairs Global at 1 site in China.
Trial summary
This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colon Cancer Patients
- What is being tested?
- This is an observational study
- Type of treatment
- Medical device
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 1 Jun 2026to 31 Dec 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with colon cancer aged 18.
Who may be able to join
- Patients pathologically confirmed with colon cancer via endoscopic biopsy.
- Patients who underwent preoperative abdominopelvic enhanced spectral CT.
- Study participant with age ≥ 18 years old.
- Study participants that have signed Informed Consent Form (ICF).
Who cannot join
- The clinical data or pathological information is considered incomplete after evaluation by the investigator.
- The investigator determined that poor image quality (e.g. obvious artifacts, missing critical scan layers) would not satisfy post-processing analysis.
- Data of patients deemed inappropriate for inclusion after evaluation by the investigator.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Sun Yat-sen cancer center
Guangzhou, Guangdong
Li, +8613926015016, lisu@sysucc.org.cn
About this study
Official title: CT Image Quality Assessment of Colon Cancer Using Spectral Precise Image Deep Learning Reconstruction
This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan.
Read the detailed description
This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan at investigational center, including retrospective and prospective data. Based on the Dose Right Index (DRI) derived from CT image data, relevant data will be collected at a 1:1 ratio for the conventional radiation dose group (RD group, DRI = 21) and the low radiation dose group (LD group, DRI = 18). A total of 100 cases of datasets is expected to be collected. All CT raw data will be transmitted to Philips after the completion of the de-identification process. For the three-phase data of the LD group (plain scan, arterial phase and venous phase), offline reconstruction will be performed using the Spectral Precise Image algorithm to generate conventional images and VMI-40 keV images. A total of six image sequences will be quantitatively and qualitatively evaluated and compared. For both groups, conventional images and VMI-40 keV images will be reconstructed using iDose4.
- Conditions
- Colon Cancer Patients
- Being tested
- This is an observational study
- Keywords
- Spectral Precise Image
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
This is an observational studyDevice
This is an observational study
What is being measured
The primary outcome is the main question the study is designed to answer.
subjective overall Image quality using 5-point Likert scale(1-5)
Radiologist will evaluate the overall image quality using 5 Likert scale ranging from 1(poor) to 5 (Excellent)
Measured: From the date of image reconstruction completion to the date of image evaluation completion, anticipated 3 Months.
Objective image quality
The objective image quality is evaluated by measuring the CT value shown in the image.
Measured: From the date reconstruction completion to the date of image evaluation completion, anticipated 3months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2026
- Study start1 Jun 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colon Cancer PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Sun Yat-Sen University Cancer Center
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07620444
- Sponsor's protocol ID
- 301160
- Status last verified
- Apr 2026
- First submitted
- 11 May 2026
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Site and Sponsor need further discussion
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CT Image Quality Assessment of Colon Cancer Using Spectral Precise Image Deep Learning Reconstruction
- ClinicalTrials.gov ID
- NCT07620444
- Acronym / sponsor ID
- 301160
- Conditions
- Colon Cancer Patients
- Keywords
- Spectral Precise Image
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Philips Clinical & Medical Affairs GlobalIndustry (pharma, biotech, devices)
- Collaborators
- Sun Yat-Sen University Cancer Center
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 2 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan.
Detailed description
This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan at investigational center, including retrospective and prospective data. Based on the Dose Right Index (DRI) derived from CT image data, relevant data will be collected at a 1:1 ratio for the conventional radiation dose group (RD group, DRI = 21) and the low radiation dose group (LD group, DRI = 18). A total of 100 cases of datasets is expected to be collected. All CT raw data will be transmitted to Philips after the completion of the de-identification process. For the three-phase data of the LD group (plain scan, arterial phase and venous phase), offline reconstruction will be performed using the Spectral Precise Image algorithm to generate conventional images and VMI-40 keV images. A total of six image sequences will be quantitatively and qualitatively evaluated and compared. For both groups, conventional images and VMI-40 keV images will be reconstructed using iDose4.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with colon cancer aged 18.
Key inclusion criteria (4 listed)
- Patients pathologically confirmed with colon cancer via endoscopic biopsy.
- Patients who underwent preoperative abdominopelvic enhanced spectral CT.
- Study participant with age ≥ 18 years old.
- Study participants that have signed Informed Consent Form (ICF).
Key exclusion criteria (3 listed)
- The clinical data or pathological information is considered incomplete after evaluation by the investigator.
- The investigator determined that poor image quality (e.g. obvious artifacts, missing critical scan layers) would not satisfy post-processing analysis.
- Data of patients deemed inappropriate for inclusion after evaluation by the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| This is an observational studyThis is an observational study | Device | – |
Primary outcome
subjective overall Image quality using 5-point Likert scale(1-5)
Time frame: From the date of image reconstruction completion to the date of image evaluation completion, anticipated 3 Months.
Radiologist will evaluate the overall image quality using 5 Likert scale ranging from 1(poor) to 5 (Excellent)
Objective image quality
Time frame: From the date reconstruction completion to the date of image evaluation completion, anticipated 3months.
The objective image quality is evaluated by measuring the CT value shown in the image.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
- Individual participant dataSharing planned: Undecided. Site and Sponsor need further discussion
Related trials for Colon Cancer Patients
RecruitingPhase 2
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
Colorectal Cancer (CRC)
Not yet recruiting
FLuorescent Angiography in REduction of Anastomotic Leak in Rectal Cancer Surgery
Rectal Cancer Patients, Rectal Cancer Surgery
Not yet recruiting
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
RecruitingPhase 2
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
Colon Cancer
Recruiting
Protein Needs Study
Colorectal Cancer, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colon Cancer Patients, run by Philips Clinical & Medical Affairs Global at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Miao Chuan Xie (+8618903050011, xiechm@sysucc.org.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
subjective overall Image quality using 5-point Likert scale(1-5) (time frame: From the date of image reconstruction completion to the date of image evaluation completion, anticipated 3 Months.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.